Monitoring of drugs with a narrow therapeutic range in ambulatory care

American Journal of Managed Care

Volumn 12, Issue 5, 2006, Pages 268-274

  Raebel, Marsha A ^a,c   Carroll, Nikki M ^a   Andrade, Susan E ^d   Chester, Elizabeth A ^b,c   Lafata, Jennifer Elston ^g   Feldstein, Adrianne ^h   Gunter, Margaret J ⁱ   Nelson, Winnie W ^j   Simon, Steven R ^e   Chan, K Arnold ^f   Davis, Robert L ^k   Platt, Richard ^e,f  

^a CLINICAL RESEARCH UNIT   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ LOVELACE CLINIC FOUNDATION   (United States)

^j HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYCLOSPORIN; DIGOXIN; LITHIUM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROCAINAMIDE; QUINIDINE; TACROLIMUS; THEOPHYLLINE; VALPROATE SEMISODIUM;

ADULT; ADVERSE DRUG REACTION; AGE; AGED; AMBULATORY CARE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSULTATION; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEART ARRHYTHMIA; HEART FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEIZURE;

AMBULATORY CARE; COHORT STUDIES; DRUG DESIGN; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICAL AUDIT; PHARMACOLOGY, CLINICAL; RETROSPECTIVE STUDIES;

EID: 33646473107     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bauer LA. Clinical pharmacokinetics and pharmacodynamics. In: DiPiro JT, Talbert RL, Yee CC, Matzke GR, Wells BC, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY: McCraw-Hill; 2002:33-54.
2. Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW. Appropriateness of antiepileptic drug level monitoring. JAMA. 1995;274:1622-1626.
3. Pearce GA, Day DO. Compliance with criteria necessary for effective drug concentration monitoring. Ther Drug Monit. 1990;12:250-257.
4. McInnes GT. The value of therapeutic drug monitoring to the practicing physician: a hypothesis in need of testing. Br J Clin Pharmacol. 1989;27:281-284.
5. Mackinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults, I: indicator development. J Manag Care Pharm. 2002;8:365-371.
6. National Committee for Quality Assurance. NCQA releases HEDIS 2006: new measures address overuse, follow-up [press release]. 2005. Available at: http://www. ncqa.org/communications/news/hedis_2006.htm. Accessed March 16, 2006.
7. Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. In: Strom B, ed. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons Inc; 2005:261-269.
8. Chan KA; HMO Research Network CERTs Patient Safety Study Investigators. Development of a multipurpose data set to evaluate potential medication errors in ambulatory settings. In: Advances in Patient Safety: From Research to Implementation. Vol 2. Rockville, Md: Agency for Healthcare Research and Quality; February 2005. AHRQ Publication 050021 (1-4). Available at: http://www.ahrq.gov/qual/advances/. Accessed March 16, 2006.
9. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A Chronic Disease Score with empirically derived weights. Med Care. 1995;33:783-795.
10. Kreiger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Geocoding and monitoring US socioeconomic inequalities in mortality and cancer incidence: does choice of area-based measure and geographic level matter? The Public Health Disparities Geocoding Project. Am J Epidemiol. 2002;156:471-482.
11. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
12. Scott SA, Falcao A, Evens RP, Elenbaas JK; DRUGDEX Editorial Staff. DRUGDEX drug evaluations: carbamazepine. In: Klasco RK, ed. DRUGDEX System. Greenwood Village, Colo: Thomson Micromedex; 2005.
13. Pitterle ME, Sorkness CA, Wiederholt JB. Use of serum drug concentrations in outpatient clinics. Am J Hosp Pharm. 1985;42:1547-1552.
14. Bussey HI, Hoffman EW. A prospective evaluation of therapeutic drug monitoring. Ther Drug Monit. 1983;5:245-248.
15. Brodie MJ, Feely J. Practical clinical pharmacology: therapeutic drug monitoring and clinical trials. BMJ. 1988;296:1110-1113.
16. McKee PJ, Larkin JG, Brodie AF, Percy-Robb IW, Brodie MJ. Five years of anticonvulsant monitoring on site at the epilepsy clinic. Ther Drug Monit. 1993;15:83-90.